

**Listing of Claims:**

1-50. (Cancelled)

51. (Previously Presented). A pharmaceutical composition comprising a sulfonate salt of paroxetine, calcium hydrogen phosphate anhydrate in the form of plate shaped crystals or agglomerates thereof, a disintegrant and a lubricant, wherein said composition does not contain lactose or microcrystalline cellulose.

52. (Previously Presented). The composition according to claim 51, wherein said composition does not contain a hydrosoluble or hydrophilic diluent.

53. (Previously Presented). The composition according to claim 51, wherein said contains said calcium hydrogen phosphate anhydrate as the only diluent.

54. (Previously Presented). The composition according to claim 51, wherein said sulfonate salt of paroxetine is paroxetine methane sulfonate.

55. (Previously Presented). The composition according to claim 51, which consists essentially of paroxetine methane sulfonate, calcium hydrogen phosphate anhydrate, sodium starch glycolate, and magnesium stearate.

56. (Previously Presented). A pharmaceutical composition comprising a sulfonate salt of paroxetine, calcium hydrogen phosphate anhydrate in the form of plate shaped crystals or agglomerates thereof, a disintegrant and a lubricant, wherein said composition has a pH within the range of 5.0 to 6.0 and said composition has an added water content of 1.2 wt% or less.

57. (Previously Presented)). The pharmaceutical composition according to claim 56, which has an added water content of 0 to 1.0 wt%.

58. (Previously Presented). The composition according to claim 56, which has an added water content of 0 to 0.8 wt%.

59. (Previously Presented). The composition according to claim 56, wherein said sulfonate salt is paroxetine methane sulfonate.